These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 24483782)

  • 21. Histone deacetylases inhibitors: conjugation to other anti-tumour pharmacophores provides novel tools for cancer treatment.
    Papavassiliou KA; Papavassiliou AG
    Expert Opin Investig Drugs; 2014 Mar; 23(3):291-4. PubMed ID: 24205827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting histone deacetylase in thyroid cancer.
    Russo D; Durante C; Bulotta S; Puppin C; Puxeddu E; Filetti S; Damante G
    Expert Opin Ther Targets; 2013 Feb; 17(2):179-93. PubMed ID: 23234477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histone deacetylase inhibitors in the treatment of lymphoma.
    Lemoine M; Younes A
    Discov Med; 2010 Nov; 10(54):462-70. PubMed ID: 21122478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anticancer activities of histone deacetylase inhibitors.
    Bolden JE; Peart MJ; Johnstone RW
    Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
    Noureen N; Rashid H; Kalsoom S
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New Insights into the Role of Histone Deacetylases as Coactivators of Inflammatory Gene Expression.
    Schmitz ML; de la Vega L
    Antioxid Redox Signal; 2015 Jul; 23(1):85-98. PubMed ID: 24359078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of histone deacetylases.
    Huang Y; Shaw PG; Davidson NE
    Methods Mol Biol; 2011; 791():297-311. PubMed ID: 21913088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histone deacetylases in modulating cardiac disease and their clinical translational and therapeutic implications.
    Wang Z; Zhao YT; Zhao TC
    Exp Biol Med (Maywood); 2021 Jan; 246(2):213-225. PubMed ID: 32727215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and therapeutic impact of HDAC6-selective inhibitors.
    Dallavalle S; Pisano C; Zunino F
    Biochem Pharmacol; 2012 Sep; 84(6):756-65. PubMed ID: 22728920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HDAC inhibitors for the treatment of cancer.
    Secrist JP; Zhou X; Richon VM
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibiting epigenetic enzymes to improve atherogenic macrophage functions.
    Van den Bossche J; Neele AE; Hoeksema MA; de Heij F; Boshuizen MC; van der Velden S; de Boer VC; Reedquist KA; de Winther MP
    Biochem Biophys Res Commun; 2014 Dec; 455(3-4):396-402. PubMed ID: 25446073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural products as zinc-dependent histone deacetylase inhibitors.
    Tan S; Liu ZP
    ChemMedChem; 2015 Mar; 10(3):441-50. PubMed ID: 25581683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Altered expression of histone deacetylases in cancer.
    Montezuma D; Henrique RM; Jerónimo C
    Crit Rev Oncog; 2015; 20(1-2):19-34. PubMed ID: 25746102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospects: histone deacetylase inhibitors.
    Dokmanovic M; Marks PA
    J Cell Biochem; 2005 Oct; 96(2):293-304. PubMed ID: 16088937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HDACi--targets beyond chromatin.
    Buchwald M; Krämer OH; Heinzel T
    Cancer Lett; 2009 Aug; 280(2):160-7. PubMed ID: 19342155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Role of HDACs in the Response of Cancer Cells to Cellular Stress and the Potential for Therapeutic Intervention.
    Alseksek RK; Ramadan WS; Saleh E; El-Awady R
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897717
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is there any therapeutic value for the use of histone deacetylase inhibitors for chronic pain?
    Wang W; Cui SS; Lu R; Zhang H
    Brain Res Bull; 2016 Jul; 125():44-52. PubMed ID: 27090944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention.
    Yang XJ; Seto E
    Oncogene; 2007 Aug; 26(37):5310-8. PubMed ID: 17694074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Class II HDACs and neuronal regeneration.
    Tang BL
    J Cell Biochem; 2014 Jul; 115(7):1225-33. PubMed ID: 24604703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histone Deacetylases Function in the Control of Early Hematopoiesis and Erythropoiesis.
    Vong P; Ouled-Haddou H; Garçon L
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.